Rentschler Biopharma expanding with 22K-sq.-ft. Milford bioreactors site
Photo | Courtesy of Rentschler Biopharma
Rentschler Biopharma celebrated the groundbreaking on its new Milford facility last year. The company appointed Mark Caswell as vice president, site head of the Milford facility.
Rentschler Biopharma, a contract development and manufacturing organization headquartered in Germany, broke ground on Wednesday on a new production facility adjacent to a current production site it operates in Milford, expected to be operational in late 2023.
The new facility, the Rentschler Biopharma Manufacturing Center US, will add 22,000 square feet of manufacturing cleanroom space and be home to four new single-use bioreactors, the company said in a Thursday announcement.
“With Rentschler Biopharma’s contribution to the production of mRNA vaccines to beat the COVID-19 virus, we have seen firsthand how important it is to have highly adaptable capacity and to have the experience and expertise needed to produce new therapeutic modalities, fast,” said Frank Mathias, CEO of Rentschler Biopharma SE, in a statement. “The U.S. expansion we have kicked off at the groundbreaking is part of our ongoing plan to strategically grow our business as we support our clients in developing and manufacturing even highly complex molecules.”
The expansion will also include growing Rentschler’s Milford workforce, although the manufacturer did not specify by how much.
Designs for the facility include upstream ballroom processing sized for production flexibility, downstream processing suites equipped with buffer storage and preparation space, as well as room to grow. The site will include, as well, expanded quality control, development and warehousing facilities, as well as the ability to provide digital and analytical services.
WBJ Web Partners
Most Recent
Most Recent
0 Comments